Upstream Bio (UPB) Projected to Post Earnings on Thursday

Upstream Bio (NASDAQ:UPB) is anticipated to announce its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.77) per share and revenue of $0.6460 million for the quarter. Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 13, 2025 at 7:00 AM ET.

Upstream Bio (NASDAQ:UPB) last issued its earnings results on Wednesday, August 6th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.13). Upstream Bio had a negative net margin of 3,836.58% and a negative return on equity of 35.90%. The firm had revenue of $0.94 million during the quarter, compared to analyst estimates of $0.32 million. On average, analysts expect Upstream Bio to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Upstream Bio Stock Down 3.2%

Shares of Upstream Bio stock opened at $25.02 on Tuesday. Upstream Bio has a 52-week low of $5.14 and a 52-week high of $29.46. The company has a market capitalization of $1.35 billion and a P/E ratio of -3.05. The company has a 50 day moving average of $19.50 and a 200 day moving average of $14.43.

Institutional Trading of Upstream Bio

Several institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets grew its stake in Upstream Bio by 229.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock worth $34,000 after buying an additional 2,158 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Upstream Bio by 71.2% in the second quarter. Bank of America Corp DE now owns 18,031 shares of the company’s stock valued at $198,000 after acquiring an additional 7,500 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Upstream Bio by 85.4% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,084 shares of the company’s stock worth $210,000 after acquiring an additional 8,788 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Upstream Bio in the 2nd quarter valued at $145,000. Finally, Invesco Ltd. raised its position in Upstream Bio by 6.4% in the 2nd quarter. Invesco Ltd. now owns 16,300 shares of the company’s stock valued at $179,000 after purchasing an additional 985 shares during the last quarter.

Analysts Set New Price Targets

UPB has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Upstream Bio in a research report on Wednesday, October 8th. Truist Financial initiated coverage on Upstream Bio in a research report on Tuesday, October 14th. They set a “buy” rating and a $47.00 price objective for the company. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Upstream Bio currently has an average rating of “Moderate Buy” and a consensus price target of $53.33.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.